

## Synthetic Amyloid Beta Peptides aid Alzheimer Investigation

A. Vandersteen, E. Hubin, and K. Broersen

Nanobiophysics Group, MIRA Institute for Biomedical Technology and Technical Medicine, Faculty of Science and Technology, University of Twente, 7500 AE Enschede, The Netherlands

VIB Switch Laboratory, Department of Cellular and Molecular Medicine, Katholieke Universiteit Leuven, Herestraat 49, Box 802, 3000 Leuven, Belgium

Structural Biology Brussels, Department of Biotechnology (DBIT), Vrije Universiteit Brussel (VUB), Pleinlaan 2, B-1050 Brussels, Belgium

VIB Department of Structural Biology, Pleinlaan 2, B-1050, Brussels, Belgium


Aggregates of the amyloid beta ( $A\beta$ ) peptide are a hallmark of the Alzheimer's disease brain. Rather than presenting a single well-defined moiety, the  $A\beta$  peptide pool is complex and composed from peptides truncated at the N-terminus and varying in length at the C-terminus. A range of synthetic amyloid beta peptides with C-terminal variation were produced to systematically investigate the role of peptide composition on aggregation. Thioflavin T binding, far-UV circular dichroism and transmission electron microscopy were used to investigate the properties of the formed aggregates.

### Introduction

Alzheimer's disease is a progressive neurodegenerative disease and one of the first symptoms includes the loss of cognitive function which generally presents itself around the age of 65. Accumulations of  $A\beta$ , a product of the processing of the amyloid precursor protein (APP), present the typical pathogenic feature in the Alzheimer's disease brain (1,2). Over the years the  $A\beta$  peptide pool has been identified as highly complex and consists, amongst others, of peptides containing 37, 38, 40, 42 and 43 amino acids (3,4), mainly as a result of an ill-defined cleavage site of the  $\gamma$ -secretase enzyme for APP. The  $A\beta$  peptide pool in patients with Alzheimer's disease tend to over represent longer  $A\beta$  peptides (42 amino acids and up) compared to healthy subjects. While it has already been reported that  $A\beta$ 1-42 aggregates more rapidly than  $A\beta$ 1-40 (5), until recently the properties of other  $A\beta$  peptides in the brain were unknown. In this work, the aggregation properties of C-terminal variations of  $A\beta$  are compared using Thioflavin T binding, circular dichroism, and transmission electron microscopy (6).


### Materials & Methods

Peptides were provided as HFIP films by JPT Peptide Technologies (Berlin, Germany). They were synthesized using an ABI 433A Peptide Synthesizer and purified by preparative high performance liquid chromatography. Purity and identity of the peptides were evaluated using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Peptides were dissolved using a sequential procedure involving 1,1,1,3,3,3-hexafluoro-2-propanol and dimethyl sulfoxide followed by incubation in 1 mM EDTA and 50 mM Tris pH 7.5 (7). Aggregation of  $A\beta$  was monitored using Thioflavin T binding, circular dichroism and transmission electron microscopy (TEM) upon incubation for 15 h, 2 weeks and 2 weeks, respectively.




### Results

The affinity of formed aggregates to bind Thioflavin T, a dye reporting on aggregate formation, was monitored upon incubation of  $A\beta$ 1-37,  $A\beta$ 1-40,  $A\beta$ 1-42 and  $A\beta$ 1-43 for 15 hours (Figure 1). The formation of Thioflavin T-positive aggregates does not correlate in a linear manner to  $A\beta$  peptide length. Short  $A\beta$ 1-37 and long  $A\beta$ 1-42 and  $A\beta$ 1-43 have similar low Thioflavin T fluorescence intensity after 15 h incubation while  $A\beta$ 1-38 and  $A\beta$ 1-40 exert five- to six-fold higher fluorescence intensity under similar conditions. A morphological description of the formed aggregates was obtained by using transmission electron microscopy (Figure 2).



All peptides have a strong propensity to self-assemble, but the morphology of the resulting aggregates varies with peptide length. Shorter peptides A $\beta$ 1-37 and A $\beta$ 1-38 form extended negatively stained and semi-flexible fibrils without obvious branching. Upon extending the peptide length towards the C-terminus, the fibrils formed gradually transform into densely stained networks in which individual strands can no longer be distinguished. Even though A $\beta$ 1-37 and A $\beta$ 1-42 show similar Thioflavin T binding properties upon aggregate formation, fibril morphologies vary strongly. To establish the conformation in terms of secondary structure of the aggregates formed, far-UV circular dichroism was employed (Figure 3). Data show a gradual conversion from random coil (negative values around 198 nm) to  $\beta$ -sheet enriched (negative peak around 210 nm) aggregates with C-terminal extension.



**Figure 3:** Aggregate secondary structure properties monitored by far-UV circular dichroism spectroscopy of A $\beta$  after 2 weeks of incubation at a peptide concentration of 25  $\mu$ M.

### Discussion & Conclusions

Synthetic A $\beta$  peptides were tested for their effect of C-terminal variation on aggregation propensity, morphology and secondary structure using Thioflavin T fluorescence, transmission electron microscopy, and far-UV circular dichroism, respectively. A $\beta$  peptides investigated in this study contained 37, 38, 40, 42 and 43 amino acids which are peptides also naturally found in the brain. Strong differences were observed in the propensity of the peptides to self-assemble and form Thioflavin-T positive aggregates largely resulting from varying morphology. Even though extensive  $\beta$ -sheet enriched aggregation was observed for A $\beta$ 1-42 and A $\beta$ 1-43 using transmission electron microscopy and circular dichroism spectroscopy, as consistent with literature, these aggregates only exert limited Thioflavin T binding (8,9). It is hypothesized that the dense networks observed for these two peptides disable direct access of the Thioflavin T dye, thereby inhibiting binding and fluorescence intensity. The A $\beta$  peptide pool in the brain is mainly composed from A $\beta$ 1-40 and A $\beta$ 1-42 which properties have been extensively studied. The presence of A $\beta$ 1-37, A $\beta$ 1-38 and A $\beta$ 1-43 in the brain has been recently recognized and, moreover, these peptides are now anticipated to play a role in modulating progress of Alzheimer's disease (10).

### References

1. "Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein." Glenner et al., *Biochem Biophys Res Commun* (1984). 120: 885-890.
2. "In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity." Pike et al., *Brain Res* (1991) 563: 311-314.

3. "Characterization of beta-amyloid peptide from human cerebrospinal fluid". Vigo-Pelfrey et al., *J Neurochem* (1993). 61: 1965-1968.
4. "Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment." Takami et al., *J Neurosci* (2009). 29: 13042-13052.
5. "Abeta40 inhibits amyloid deposition in vivo". Kim et al., *J Neurosci* (2007). 27: 627-633.
6. "A comparative analysis of the aggregation behaviour of amyloid- $\beta$  peptide variants." Vandersteen et al., *FEBS Letters* (2012). 586: 4088-4093.
7. "A standardized and biocompatible preparation of aggregate-free amyloid beta peptide for biophysical and biological studies of Alzheimer's disease." Broersen et al., *PEDS* (2011). 24: 743-750.
8. "The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease." Jarrett et al., *Biochemistry* (1993). 32: 4693-4697.
9. "Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths." Snyder et al., *Biophys J* (1994). 67: 1216-1228.
10. "Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease." Portelius et al., *Acta Neuropathol* (2010). 120: 185-193.

### The Author



**Kerensa Broersen-Nutma**  
k.broersen@utwente.nl  
Faculty of Science and Technology,  
University of Twente  
& MIRA Institute for Biomedical  
Technology and Technical Medicine,  
Enschede  
The Netherlands

Kerensa Broersen-Nutma is working as an assistant professor at the University of Twente and the MIRA Institute for Biomedical Technology and Technical Medicine. She got her PhD from Wageningen University in The Netherlands on the topic of folding, unfolding and aggregation of food proteins and currently is supervising a research team investigating the role of amyloid beta peptide in Alzheimer's disease.

### The Company

**JPT Peptide Technologies** is a DIN ISO 9001:2015 certified provider of innovative peptide solutions for: cellular and humoral immune monitoring, seromarker discovery & validation, vaccine target discovery, peptide lead identification & optimization, targeted proteomics, and enzyme profiling.

### Contact us for further information!

email: [peptide@jpt.com](mailto:peptide@jpt.com)  
phone: +49-30-322980-7878

### Please visit us online at:

[www.jpt.com](http://www.jpt.com)